Sorafenib Help Liver Cancer Patients
 |
| Synonyms And Synonyms |
PATIENTS with advanced liver cancer (hepatocellular carcinoma, HCC) has a greater expectation to extend and maintain the quality of life. With a focus on cancer therapy using target drug Sorafenib, HCC patients may mengingkatkan survival by 47 percent.
"Sorafenib has become the standard system for the treatment of advanced stage liver cancer. It is the only therapy that has shown an increased survival rate for people with liver cancer in the world and also in Indonesia," said Professor Ali Sulaiman SpDP-KGEH, from the Division Hematology Department of Internal Medicine, University of Indonesia Faculty of Medicine Hospital Ciptomangunkusumo (FKUI / RSCM) in Jakarta on Thursday (26 / 6).
Sorafenib ability to extend life expectancy, continued Prof. Ali, can be seen from the results of various research including international research SHARP phase-3 performed on patients with liver cancer in the U.S., Europe and Australia / New Zealand showed Sorafenib significantly improve the quality of survival sebasar 44 percent.
In a similar study, also evaluating the efficacy and safety compared with placebo Sorafenib performed on 226 patients with HCC patients in the Asia Pacific region, namely Phase III Asia Pacific Study, found that Sorafenib significantly increases survival by 47.3 percent on-stage liver cancer patients information.
"From the existing data, it appears that the extension of Sorafenib showed increased survival rate. Comparison between research in Asia Pacific with the results of international trials in the U.S. Sharp showed similar success rates, although patients in the Asia Pacific region have a more alarming health status and more metastases ", said Dr. Hady Sharif, Head of Specialty Care Bayer Schering Pharma Indonesia.
Sorafenib is an oral therapy targeting tumor cells and tumor bleeding system for consumption in the long term. In addition to treating advanced stage liver cancer, the drug is also used for the treatment of advanced stage kidney cancer. Sorafenib has been approved in more than 40 countries for the treatment for patients with liver cancer that can not be operated on and in over 70 countries for the treatment for patients with advanced kidney cancer.
Sorafenib works by targeting tumor cells and tumor bleeding system. In a preclinical test, Sorafenib proved able to inhibit the two types of kinases that is profilerasi cells and angiogenesis (blood vessel formation) in which both play a major role in the process of cancer growth. This process is also important for normal cells, so that the target of Sorafenib therapy can also affect some normal cells.
According to Prof Ali, though quite safe to use. Sorafenib still have side effects for its users. Eefek possible side include diarrhea, pain, burning, and numbness. "When some of the symptoms appear, doctors usually will adjust the dose and stop the medication for semnetara time," he said.
In November 2007, Sorafenib has been approved by the U.S. Food Drug Administration (FDA) for treatment of patients with liver cancer is inoperable and has recently also been approved in more than 40 countries. While in Indonesia, Sorafenib has been approved POM RI in April 2008 for the treatment of patients with advanced stage liver cancer that can not be operated on (HCC).
With advanced liver cancer (hepatocellular carcinoma) by Prof. Ali is now included in the 6 large the most frequent cause of cancer deaths in Indonesia. The number of sufferers is usually aligned with a number of people with hepatitis B and chronic hepatitis C, two groups at highest risk. Most of the patients diagnosed with cancer is usually unknown and symptoms initially come to the doctor already in an advanced stage.
In the early stages, liver cancer can be treated by surgery to remove cancerous tissue. In addition, liver cancer patients undergoing chemotherapy. But at an advanced stage, patients can not mejalani action because cancer cells have spread.
"The general came to the hospital too late. About 80 percent of patients with inoperable again, which is usually treated probably only about 30-40 percent," he said.
"Sorafenib has become the standard system for the treatment of advanced stage liver cancer. It is the only therapy that has shown an increased survival rate for people with liver cancer in the world and also in Indonesia," said Professor Ali Sulaiman SpDP-KGEH, from the Division Hematology Department of Internal Medicine, University of Indonesia Faculty of Medicine Hospital Ciptomangunkusumo (FKUI / RSCM) in Jakarta on Thursday (26 / 6).
Sorafenib ability to extend life expectancy, continued Prof. Ali, can be seen from the results of various research including international research SHARP phase-3 performed on patients with liver cancer in the U.S., Europe and Australia / New Zealand showed Sorafenib significantly improve the quality of survival sebasar 44 percent.
In a similar study, also evaluating the efficacy and safety compared with placebo Sorafenib performed on 226 patients with HCC patients in the Asia Pacific region, namely Phase III Asia Pacific Study, found that Sorafenib significantly increases survival by 47.3 percent on-stage liver cancer patients information.
"From the existing data, it appears that the extension of Sorafenib showed increased survival rate. Comparison between research in Asia Pacific with the results of international trials in the U.S. Sharp showed similar success rates, although patients in the Asia Pacific region have a more alarming health status and more metastases ", said Dr. Hady Sharif, Head of Specialty Care Bayer Schering Pharma Indonesia.
Sorafenib is an oral therapy targeting tumor cells and tumor bleeding system for consumption in the long term. In addition to treating advanced stage liver cancer, the drug is also used for the treatment of advanced stage kidney cancer. Sorafenib has been approved in more than 40 countries for the treatment for patients with liver cancer that can not be operated on and in over 70 countries for the treatment for patients with advanced kidney cancer.
Sorafenib works by targeting tumor cells and tumor bleeding system. In a preclinical test, Sorafenib proved able to inhibit the two types of kinases that is profilerasi cells and angiogenesis (blood vessel formation) in which both play a major role in the process of cancer growth. This process is also important for normal cells, so that the target of Sorafenib therapy can also affect some normal cells.
According to Prof Ali, though quite safe to use. Sorafenib still have side effects for its users. Eefek possible side include diarrhea, pain, burning, and numbness. "When some of the symptoms appear, doctors usually will adjust the dose and stop the medication for semnetara time," he said.
In November 2007, Sorafenib has been approved by the U.S. Food Drug Administration (FDA) for treatment of patients with liver cancer is inoperable and has recently also been approved in more than 40 countries. While in Indonesia, Sorafenib has been approved POM RI in April 2008 for the treatment of patients with advanced stage liver cancer that can not be operated on (HCC).
With advanced liver cancer (hepatocellular carcinoma) by Prof. Ali is now included in the 6 large the most frequent cause of cancer deaths in Indonesia. The number of sufferers is usually aligned with a number of people with hepatitis B and chronic hepatitis C, two groups at highest risk. Most of the patients diagnosed with cancer is usually unknown and symptoms initially come to the doctor already in an advanced stage.
In the early stages, liver cancer can be treated by surgery to remove cancerous tissue. In addition, liver cancer patients undergoing chemotherapy. But at an advanced stage, patients can not mejalani action because cancer cells have spread.
"The general came to the hospital too late. About 80 percent of patients with inoperable again, which is usually treated probably only about 30-40 percent," he said.
By. Synonyms And Synonyms
Sharing is sexy
Previous Entries
0 komentar for this post
Leave a reply